Our current therapies resulted in a substantial decrease in TNF-α and IL-6 levels, with the highest inhibition observed in the groups treated with combined BBR and CAF, suggesting their potential neuroprotective properties in the midbrain to mitigate behavioral deficits induced in the PD model. This evidence concerns the gene TNF and Parkinson disease.